Search | Clinical Trials Finder

Conditions: Endometriosis
Interventions: OG-6219, Placebo; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, Connecticut + 22 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Tarzana, California • Torrance, California + 4 more

Conditions: Healthy
Interventions: granisetron; Drug
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0); Biological
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more

Conditions: Prior Acute Myocardial Infarction, Evidence of Systemic Inflammation (C Reactive Protein Plasma >2 mg/l), Reduced Left Ventricle Ejection Fraction (<50%), Symptoms of Heart Failure (NYHA Class II-III)
Interventions: Cardiopulmonary exercise test, Echocardiogram; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 110 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy
Interventions: ACT-246475, Clopidogrel, Prasugrel, Placebo, Ticagrelor; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Type 2 Diabetes Mellitus, Diabetes
Interventions: REMD-477; Biological
Lead sponsor: REMD Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Miami, Florida • San Antonio, Texas • Renton, Washington

Conditions: Primary Sclerosing Cholangitis (PSC)
Interventions: Simtuzumab, Placebo; Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 43
States / cities: Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 34 more

Conditions: Heart Failure With Normal Ejection Fraction
Interventions: Active lozenge, Placebo; Dietary Supplement · Drug
Lead sponsor: MaineHealth; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rockport, Maine

Conditions: Social Phobia
Interventions: Social Effectiveness Therapy for Children (SET-C), Fluoxetine, Pill Placebo; Behavioral · Drug
Lead sponsor: University of Central Florida; Other
Eligibility: 8 Years to 16 Years
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: University of Maryland, College Park, Maryland

Conditions: Asthma
Interventions: PF-07275315, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 36
States / cities: Mobile, Alabama • Chandler, Arizona • Lancaster, California + 29 more

Conditions: Psoriasis
Interventions: Ixekizumab, Placebo; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 31
States / cities: Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more

Conditions: Community-acquired Infection
Interventions: GSK2251052 750 mg, GSK2251052 1500 mg, GSK2251052 1500 mg BID, GSK2251052 2250 mg, GSK2251052 3000 mg, GSK2251052 0.9% saline; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: HIV Infections
Interventions: Sub C gp140 Vaccine, MF59C.1 Adjuvant, Sodium chloride; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Healthy Participants
Interventions: INCB000631, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Irritable Bowel Syndrome
Interventions: DDP733; Drug
Lead sponsor: Dynogen Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 62
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 53 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Frexalimab, Placebo, Insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 35 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 14
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more

Conditions: Chronic Hepatitis C Infection
Interventions: GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more

Conditions: Hidradenitis Suppurativa
Interventions: CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 8
States / cities: Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more

Conditions: Hepatitis C
Interventions: XTL 6865; Drug
Lead sponsor: XTL Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Indianapolis, Indiana • New York, New York • Chapel Hill, North Carolina + 1 more

Conditions: Hepatitis C
Interventions: TMC435; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 15
States / cities: Bakersfield, California • Los Angeles, California • San Diego, California + 12 more

Conditions: Mild Traumatic Brain Injury, Suicidal Ideation, Impulsivity
Interventions: intermittent theta burst stimulation, placebo intermittent theta burst stimulation; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 22 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions: MTP-101P, Vancomycin, Miralax, Antacid, Placebo MTP-101P, Placebo Vancomycin; Combination Product
Lead sponsor: Gut-Brain-Axis Therapeutics Inc.; Other
Eligibility: 4 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Ulcerative Colitis (UC)
Interventions: TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 38
States / cities: Chula Vista, California • La Jolla, California • Lancaster, California + 34 more

Search by objective public record fields.

A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus

Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)

Treatment of HFpEF With Nitrate Supplement

Treatment of Childhood Social Phobia

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

A Study in Participants With Moderate to Severe Psoriasis

A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers

Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants

A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

Frontal iTBS for Impulsivity and Suicidal Ideation in Veterans With Mild Traumatic Brain Injury

Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders

Efficacy & Safety of TD-1473 in Ulcerative Colitis